Scholars Central

Research articlePublished 29 Mar 2023

Conversion from hemodialysis to hemodiafiltration affects the innate immunity of individuals with chronic kidney disease

Authors: Flávio José Dutra de Moura, David da Silva Nunes, Beatriz Guterres Rodrigues de Sousa, Jaqueline Santos Ribeiro, Jonas Gonzaga do Nascimento, Amanda Macedo, Eloah Soares Povill Souza, Marcus Henrique Oliveira, Fernando Fontes de Souza, Vanessa Simioni Faria, Shirley Claudino Pereira Couto, Tatiana Karla de Santos Borges, Joel Paulo Russomano Veiga, Selma Aparecida Souza Kuckelhaus

American Journal of Advanced Drug Delivery

Volume 11 · Issue 1 · Pages 1–9

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Once a diagnosis of chronic kidney disease (CKD) stage 5 is confirmed, possible treatments include kidney replacement therapies, such as hemodialysis (HD) and hemodiafiltration (HDF). HD removes low-molecular-weight molecules, while HDF purges small and large molecules, favoring the reduction of oxidative stress. Objectives: This study evaluated the hematological, biochemical and immunological parameters of individuals with CKD treated with HD who later converted to HDF. Methods: This is a descriptive, retrospective and comparative study carried out with 25 individuals whose HD treatment was later converted to HDF (convenience sample). Results: Data were analyzed in blood samples (cells and serum). Patient`s etiologies were type II Diabetes Mellitus (DM) (48%) and Systemic Arterial Hypertension (SAH) (32%). HDF reduced serum levels of erythropoietin (EPO), glucose, aspartate aminotransferase, and ꞵ2-microglobulin and the EPO resistance index and increased levels of alkaline phosphatase and C-reactive protein. HDF normalized the phagocytic index with 5 or 20 yeasts/ cell and normalized the stimulated corpuscular index but increased TNF and IL-4 production compared to HD. Furthermore, HDF normalized the basal production of O2 and its production in the absence of phagocytosis, but when compared to HD, HDF increased the production of O2 in the presence or absence of yeast ingestion. Conclusion: Our results indicate that HDF is efficient in treating patients with CKD by improving most of immunological markers and maintaining the treatment efficacy. Considering that HDF is rarely used in Brazil, this a study is suggested to promote greater visibility and acceptance of HDF among patients and the medical community, aiming at its future implementation in the public health system.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalAmerican Journal of Advanced Drug Delivery
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Flávio José Dutra de Moura”
  • BylineArticles whose byline prints “David da Silva Nunes”
  • BylineArticles whose byline prints “Beatriz Guterres Rodrigues de Sousa”
  • BylineArticles whose byline prints “Jaqueline Santos Ribeiro”
  • BylineArticles whose byline prints “Jonas Gonzaga do Nascimento”
  • BylineArticles whose byline prints “Amanda Macedo”
  • BylineArticles whose byline prints “Eloah Soares Povill Souza”
  • BylineArticles whose byline prints “Marcus Henrique Oliveira”